{"title": "SARS-CoV-2 invades host cells via a novel route: CD147-spike protein", "doi": "10.1101/2020.03.14.988345", "citation_id": "2020.03.14.988345v1", "date": "2020-03-14", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.03.14.988345", "abstract": "<p>Currently, COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been widely spread around the world; nevertheless, so far there exist no specific antiviral drugs for treatment of the disease, which poses great challenge to control and contain the virus. Here, we reported a research finding that SARS-CoV-2 invaded host cells via a novel route of CD147-spike protein (SP). SP bound to CD147, a receptor on the host cells, thereby mediating the viral invasion. Our further research confirmed this finding. First, in vitro antiviral tests indicated Meplazumab, an anti-CD147 humanized antibody, significantly inhibited the viruses from invading host cells, with an EC50 of 24.86 \u03bcg/mL and IC50 of 15.16 \u03bcg/mL. Second, we validated the interaction between CD147 and SP, with an affinity constant of 1.85E-07M. Co-Immunoprecipitation and ELISA also confirmed the binding of the two proteins. Finally, the localization of CD147 and SP was observed in SARS-CoV-2 infected Vero E6 cells by immuno-electron microscope. Therefore, the discovery of the new route CD147-SP for SARS-CoV-2 invading host cells provides a critical target for development of specific antiviral drugs.</p>", "twitter_description": "Currently, COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been widely spread around the world; nevertheless, so far there exist no specific antiviral drugs for treatment of the disease, which poses great challenge to control and contain the virus. Here, we reported a research finding that SARS-CoV-2 invaded host cells via a novel route of CD147-spike protein (SP). SP bound to CD147, a receptor on the host cells, thereby mediating the viral invasion. Our further research confirmed this finding. First, in vitro antiviral tests indicated Meplazumab, an anti-CD147 humanized antibody, significantly inhibited the viruses from invading host cells, with an EC50 of 24.86 \u03bcg/mL and IC50 of 15.16 \u03bcg/mL. Second, we validated the interaction between CD147 and SP, with an affinity constant of 1.85\u00d710\u22127M. Co-Immunoprecipitation and ELISA also confirmed the binding of the two proteins. Finally, the localization of CD147 and SP was observed in SARS-CoV-2 infected Vero E6 cells by immuno-electron microscope. Therefore, the discovery of the new route CD147-SP for SARS-CoV-2 invading host cells provides a critical target for development of specific antiviral drugs.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/03/14/2020.03.14.988345.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.03.14.988345v1", "access_rights": "restricted", "authors": ["Ke Wang", "Wei Chen", "Yu-Sen Zhou", "Jian-Qi Lian", "Zheng Zhang", "Peng Du", "Li Gong", "Yang Zhang", "Hong-Yong Cui", "Jie-Jie Geng", "Bin Wang", "Xiu-Xuan Sun", "Chun-Fu Wang", "Xu Yang", "Peng Lin", "Yong-Qiang Deng", "Ding Wei", "Xiang-Min Yang", "Yu-Meng Zhu", "Kui Zhang", "Zhao-Hui Zheng", "Jin-Lin Miao", "Ting Guo", "Ying Shi", "Jun Zhang", "Ling Fu", "Qing-Yi Wang", "Huijie Bian", "Ping Zhu", "Zhi-Nan Chen"]}